Search clinical trials for: AX-202

Total 3058 results

Arxx Therapeutics

Recruiting

A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

Healthy Volunteers | Mild to Moderate Psoriasis

United Kingdom
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
Axalbion SA

Completed

AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects

Healthy

United Kingdom
Artax Biopharma Inc

Recruiting

Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United Kingdom
Axalbion SA

Recruiting

A Study of Efficacy and Safety of AX-8 in Chronic Cough

Chronic Cough

United Kingdom
Allievex Corporation

Enrolling by invitation

Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

MPS III B

United States, Germany, Turkey, United Kingdom, Colombia
HidraMed Solutions Ltd

Completed

HidraWear AX HS Study

Hidradenitis Suppurativa | Hidradenitis

Ireland
Artax Biopharma Inc
Simbec-Orion Group

Completed

A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses

Autoimmune Diseases

United Kingdom
Artax Biopharma Inc
Simbec Research

Completed

Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects

Healthy

United Kingdom
Artax Biopharma Inc
Simbec Research; ORION Clinical Services; Packaging Coordinators Inc; Centro de...

Completed

Safety Study of Immune System Modulator for Autoimmune Diseases

Healthy Volunteers

United Kingdom
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Allievex Corporation

Active, not recruiting

A Treatment Extension Study of Mucopolysaccharidosis Type IIIB

Mucopolysaccharidosis Type IIIB | MPS III B

Germany, United States, Turkey, United Kingdom, Colombia, Spain, Taiwan
Centre Psychothérapique de Nancy
Institut National de la Santé Et de la Recherche Médicale, France

Not yet recruiting

Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia (SensoSchiz)

Schizophrenia | Sensory Processing Disorder
Allievex Corporation

Completed

A Treatment Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Mucopolysaccharidosis Type IIIB | MPS III B

United States, Taiwan, Spain, Colombia, Germany, United Kingdom, Turkey
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Yoav D. Livney
Israel Innovation Authority

Completed

Evaluating Astaxanthin Bioavailability, and a New Technology for Improving it, Using Natural Food Materials Only

Bioavailability

Israel
ARYx Therapeutics

Completed

Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers

Atrial Fibrillation

United States, Canada
Celgene

Completed

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Healthy

United States
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
Yusuf Menda
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Not yet recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Carcinoid Tumor Lung | Neuroendocrine Tumor of the Lung | Carcinoma, Small-Cell Lung

United States
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Clearside Biomedical, Inc.

Completed

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Neovascular Age-related Macular Degeneration

United States
REGENXBIO Inc.

Recruiting

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Alpine Immune Sciences, Inc.

Terminated

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)

Lymphoma | Advanced Solid Tumor

United States, Australia
GenSpera, Inc.

Completed

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme

United States
GenSpera, Inc.

Completed

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Neothetics, Inc

Unknown

An Open-Label Study to Evaluate Retreatment With LIPO-202

Central Abdominal Bulging

United States
Sarang K. Yoon, DO, MOH
Novavax; Westat

Recruiting

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection (BEEHIVE)

COVID-19 | SARS CoV 2 Infection | Vaccine-Preventable Diseases | Upper Respiratory Tract Infection | Upper Respiratory Disease

United States
Devalingam Mahalingam
GenSpera, Inc.

No longer available

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
McMaster University
Canadian Institutes of Health Research (CIHR)

Recruiting

Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1 (RIPPLE-C)

Diabetes Mellitus | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Osteoarthritis | Dementia | Congestive Heart Failure | Depression, Anxiety

Canada
ILIAS Biologics Inc.

Completed

A Study to Evaluate the Safety and Tolerability of ILB-202

Healthy

Australia
Akron Molecules AG

Completed

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

Osteoarthritis

Austria
Immune-Onc Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CMML | AML With Monocytic Differentiation

United States
GenSpera, Inc.
Saint John's Cancer Institute

Withdrawn

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Glioblastoma

United States
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
Inversago Pharma Inc.

Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Metabolic Syndrome

Canada
GenSpera, Inc.

Completed

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Clear Cell Renal Cell Carcinoma

United States
GenSpera, Inc.

Completed

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

Prostatic Neoplasms

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Oui Therapeutics, Inc.
National Institute of Mental Health (NIMH)

Enrolling by invitation

A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic

Suicidal Ideation | Suicide, Attempted

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Federico II University

Completed

Plasma SCFAs After Fermentable Cereal Fibres - A Postprandial Study (FIFERM)

Overweight and Obesity

Italy
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
Northwestern University
Brain & Behavior Research Foundation; Neurocentria, Inc.

Completed

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Bial - Portela C S.A.

Completed

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

Parkinson's Disease

United Kingdom
Seoul National University Hospital

Completed

NuGa (Nutrition for Gastric Cancer Patients)

Gastric Cancer

Korea, Republic of
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

Parkinson's Disease

United Kingdom
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States

Search clinical trials for: AX-202

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations